Month: July 2020

JOHNS CREEK, Ga., July 29, 2020 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering multi-regional less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today reported second quarter 2020 financial results.  Diluted earnings per share in the quarter were $1.07 compared to $1.40 in the second quarter of 2019.Highlights from the second quarter operating results were as follows:Second Quarter 2020 Compared to Second Quarter 2019 ResultsRevenue was $418.1 million, a 9.9% decreaseOperating income was $35.7 million, a 30.3% decreaseOperating ratio of 91.5 compared to 89.0LTL shipments per workday decreased 9.7%LTL tonnage per workday decreased by 8.9%LTL revenue per hundredweight decreased 0.6%LTL revenue per shipment rose 0.3% to $235.08“Our second quarter results were...

NORWALK, Conn., July 29, 2020 (GLOBE NEWSWIRE) — Reed’s Inc. (Nasdaq: REED), owner of the nation’s leading portfolio of handcrafted, all-natural beverages, today announced that it intends to issue its financial results for the second quarter ended June 30, 2020 after the market close on Monday, August 10, 2020.Following the release, members of Reed’s, Inc. senior management team will host a conference call with financial analysts and investors at 4:30 p.m. Eastern Time. This conference call can be accessed via a link on Reed’s investor website at http://investor.reedsinc.com/ under the “Events & Presentations” section or directly at http://public.viavid.com/index.php?id=140757. To listen to the live call over the Internet, please go to Reed’s website at least 15 minutes early to register, download and...

TORONTO, July 29, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the incorporation of the National Health Service’s (NHS) mandated daily review and daily situation report (SITREP) into its proprietary MCAP (Making Care Appropriate for Patients) Clinical Utilization Review solution.VitalHub has worked closely with the National Health Service England and National Health Service Improvement to embed their mandated daily review and daily Situation report (SITREP) into the Company’s patient flow software, offering a streamlined and efficient solution that takes frontline staff 15 – 30 seconds per patient, per day, to complete. The MCAP tool saves significant clinical time and resource for frontline staff and typically identifies 2x the number of patients for flow than current...

Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes diseaseA rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 2020NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced the publication of a study, “Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease” in Molecular Genetics and Metabolism Reports. The study was published online in July 2020.The study assessed the analytic validity of an ATP7A targeted next generation DNA sequencing assay as a potential newborn screen for Menkes...

• Revenue:$46.5 million for Q2 2020$93.0 million for H1 2020• Net cash from operating activities:$26.7 million for Q2 2020$47.7 million for H1 2020• Adjusted EBITDA:$14.3 million for Q2 2020$33.4 million for H1 2020• Acquired five drybulk vessels following the liquidation of Navios Europe II• $0.05 per unit cash distribution for Q2 2020MONACO, July 29, 2020 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo vessels, today reported its financial results for the second quarter and six month periods ended June 30, 2020.Angeliki Frangou, Chairman and Chief Executive Officer of Navios Partners, stated, “While the Pandemic greatly affected businesses, countries, and people all over the world, the Navios family continues to persevere. For the second quarter...

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.About Sol-Gel TechnologiesSol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical...

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that on July 27, 2020, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a grace period of 180 calendar days, through January 25, 2021, to evidence compliance with the Rule....

CALGARY, Alberta, July 29, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) will host a live conference call to discuss second quarter results on Thursday, August 6, 2020 at 7 am MDT (9 am EDT, 6 am PDT).The conference call will include a brief presentation from FLYHT’s CEO Bill Tempany and CFO Alana Forbes followed by a question and answer session.To access the conference call by phone within Canada and the U.S.A., the toll-free number is 1-800-319-4610. Outside Canada and the U.S.A., dial 1-604-638-5340. Callers should dial in 5 to 10 minutes prior to the scheduled start time.Management will accept questions by telephone and e-mail. Individuals wishing to ask a question during the call can do so by pressing *1. Questions can be emailed in advance or during the conference...

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive prenatal screening (NIPS) test. The proprietary AMPLIFY process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mother’s blood. AMPLIFY technology enables more accurate detection of fetal chromosome abnormalities. In the analytical validation involving samples from more than 1,000 pregnant women, fetal fraction is 2.3 times greater on average with AMPLIFY than with standard NIPS. This improvement reduces false positive and false negative results—including for...

Read full releaseMIAMI, FL, July 29, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce the expansion of the Company’s PharmCo branded pharmacy operations and presence in the Orlando metropolitan area. The Company is moving out of its current Orlando pharmacy location, which is a 700 square-foot mini-pharmacy operating under the “Five Star” brand designation, to a 3,700 square-foot full-size pharmacy that will open under the PharmCo brand designation.The Company is also very pleased to report that this move, which represents an expansion in property size of more than 400%, will not increase monthly lease costs.Carlos Rangelcarlosr@pharmcorx.com